NCT05235100 2025-12-11
SPARE-02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
Clinical Trials
12 trialsNCT04072042 2025-05-14
BIOVAS
Ruijin Hospital
Phase 2 Recruiting
NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
NCT03711279 2024-02-29
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT04012827 2022-09-07
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT04447274 2020-06-25
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
ChineseAMS
Phase 2 Unknown
NCT03104335 2020-05-19
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Peking University People's Hospital
Phase 2 Withdrawn
NCT04126811 2019-10-15
Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04126993 2019-10-15
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03539172 2018-05-30
RASS
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT03121846 2017-05-22
Mesylate Apatinib for Stage â…£ STS After Failure of Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03064243 2017-02-27
A Phase II Study of Apatinib in STS Patients
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Phase 2 Unknown